Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Noninvasive markers of liver fibrosis in drug users with Hep C

FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis in injection drug users with Hep C, reports this month's Hepatology.

News image

Most Hepatitis C virus infections are acquired by injection drug use.

Dr Lucy Wilson and colleagues from the USA assessed prospective data on the progression of liver fibrosis.

Baseline liver biopsies were obtained from 1996 to 1998 on a random sample of 210 out of 1667 Hepatitis C virus-positive injection drug users.

Subjects were followed biannually, with a second biopsy offered to those eligible.

Among 119 prospectively followed injection drug users, 96% were African American, and 97% were Hepatitis C virus genotype 1a/b.

A further 27% were HIV-infected, with a median age of 42 years.

Paired biopsies were scored from 0 to 6.

The research team defined significant fibrosis was as score 3 or greater.

Progression of fibrosis was defined as an increase 2 or more units or clinical evidence of end-stage liver disease.

The predictive value for alanine aminotransferase specificities was 73%
Hepatology

The team's predictive values of blood markers include FibroSURE, aspartate aminotransferase-to-platelet-ratio index and alanine aminotransferase.

The researchers assessed the detection of contemporaneous and future liver fibrosis.

The team noted that 91% did not have significant liver fibrosis at first biopsy.

The researchers' predictive value for detecting insignificant fibrosis at first biopsy was greater than 95% for FibroSURE.

The predictive value for aminotransferase-to-platelet-ratio index, and alanine aminotransferase specificities were 73%.

After 4 years median follow-up, 21% had progression of fibrosis.

The researchers observed that this was significantly associated with serum level of Hepatitis C virus RNA and alanine aminotransferase.

No serological test had a predictive value greater than 40% for contemporaneous or future significant fibrosis.

Initial biopsy result had only a 30% value for predicting future significant fibrosis.

Dr Wilson's team concluded, “Significant liver fibrosis and progression were detected in some, but not most, injection drug users in this cohort.”

“In this setting with low fibrosis prevalence, FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis.”

“However, further work is needed to find noninvasive markers of significant liver fibrosis.”

Hepatol 2006: 43(4): 788-95
05 April 2006

Go to top of page Email this page Email this page to a colleague

 28 January 2015

Advanced search
 28 January 2015 
Metabolic syndrome in celiac disease
 28 January 2015 
Remission in Crohn's disease
 28 January 2015 
Surgery and quality of life in rectal cancer
 27 January 2015 
Outcomes for liver transplantation
 27 January 2015 
Psychological distress and fecal composition in IBS
 27 January 2015 
Risk of upper GI cancers in GERD
 26 January 2015 
Breath analysis for IBD
 26 January 2015 
Fecal microbiota transplantation
 26 January 2015 
Antidepressants and GERD
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 23 January 2015 
Fecal microbiota transplantation
 22 January 2015 
NASH and lipid improvements
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 16 January 2015 
Fecal incontinence
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 18 December 2014 
Assessment of Crohn's disease activity
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 17 December 2014 
Non-invasive measures of fatty liver

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us